Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Pathology, chemoprevention, and preclinical models for target validation in Barrett esophagusCancer Research.  78:3747-3754. 2018
2018 Myeloid-derived suppressor cells impair B cell responses in lung cancer through IL-7 and STAT5Journal of Immunology.  201:278-295. 2018
2017 Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironmentScientific Reports.  7. 2017
2017 Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.Blood Advances.  1:2375-2385. 2017
2017 Effects of cellular methylation on transgene expression and site-specific integration of adeno-associated virusGenes.  8. 2017
2017 Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stressFederation proceedings.  31:1608-1619. 2017
2017 Location of tumor affects local and distant immune cell type and number:Immunity, Inflammation and Disease.  5:85-94. 2017
2017 Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activityOncotarget.  8:47675-47690. 2017
2017 Resveratrol induces mitochondria-mediated, caspaseindependent apoptosis in murine prostate cancer cellsOncotarget.  8:20895-20908. 2017
2016 Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascadeBONE.  93:113-124. 2016
2016 Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophagesProstate.  76:624-636. 2016
2016 Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironmentOncotarget.  7:75407-75424. 2016
2015 SOCS3 deficiency in myeloid cells promotes tumor development: Involvement of STAT3 activation and myeloid-derived suppressor cellsCancer Immunology Research.  3:727-740. 2015
2015 Endostatin: A novel inhibitor of androgen receptor function in prostate cancerProceedings of the National Academy of Sciences.  112:1392-1397. 2015
2015 Variants of osteoprotegerin lacking trail binding for therapeutic bone remodeling in osteolytic malignanciesCell Growth and Differentiation.  13:819-827. 2015
2014 Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancerPLoS ONE.  9. 2014
2014 Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of merkel cell carcinoma and correlation with prognosisRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.  55:1057-1062. 2014
2014 The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancerOncoImmunology.  3. 2014
2013 Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathwaysCancer Research.  73:6609-6620. 2013
2013 Myeloid-derived suppressor cells as osteoclast progenitors: A novel target for controlling osteolytic bone metastasisCancer Research.  73:4606-4610. 2013
2013 Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone diseaseOncoImmunology.  2. 2013
2013 Muscle-directed anti-Aβ Single-Chain Antibody Delivery Via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse modelJournal of Molecular Neuroscience.  49:277-288. 2013
2013 Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft boneBiomaterials.  34:1506-1513. 2013
2013 Role of plasmacytoid dendritic cells in breast cancer bone disseminationOncoImmunology.  2. 2013
2013 Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancerCancer Research.  73:672-682. 2013
2012 Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cellsJournal of Immunology.  189:4258-4265. 2012
2012 Bone healing by endogenous stem cell mobilizationBONE.  51:635. 2012
2012 DiVerential eVects of low-dose decitabine on immune eVector and suppressor responses in melanoma-bearing miceCancer Immunology, Immunotherapy.  61:1441-1450. 2012
2012 Noggin is novel inducer of mesenchymal stem cell adipogenesis: Implications for bone health and obesityJournal of Biological Chemistry.  287:12241-12249. 2012
2012 Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defectBONE.  50:1012-1018. 2012
2011 Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonistsCancer Gene Therapy.  18:850-858. 2011
2011 Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancerPLoS ONE.  6. 2011
2011 LL-37 as a therapeutic target for late stage prostate cancerProstate.  71:659-670. 2011
2011 Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapyClinical Cancer Research.  17:538-549. 2011
2011 Anti-amyloid-β single-chain antibody brain delivery via aav reduces amyloid load but may increase cerebral hemorrhages in an alzheimer's disease mouse modelJournal of Alzheimer's Disease.  27:23-28. 2011
2010 Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cellsCancer Letters.  298:238-249. 2010
2010 Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonistsVaccine.  28:7837-7843. 2010
2010 Merkel cell carcinoma: Correlation of KIT expression with survival and evaluation of KIT gene mutational statusHuman Pathology.  41:1405-1412. 2010
2010 Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeletonJournal of Cellular Biochemistry.  111:249-257. 2010
2010 Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defectMolecular Therapy.  18:1026-1034. 2010
2010 Therapeutic potential of genetically modified adult stem cells for osteopeniaGene Therapy.  17:105-116. 2010
2009 Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasisClinical Cancer Research.  15:7175-7185. 2009
2009 Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4Laboratory Investigation.  89:1221-1228. 2009
2009 High Cks1 expression in transgenic and carcinogeninitiated mammary tumors is not always accompanied by reduction in p27Kip1International Journal of Oncology.  34:1425-1431. 2009
2009 Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor statusProstate.  69:1055-1066. 2009
2009 Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis.Journal of Clinical Oncology.  27:6027. 2009
2009 Pulmonary Angiogenesis in a Rat Model of Hepatopulmonary SyndromeGastroenterology.  136:1070-1080. 2009
2008 Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cellsHuman Gene Therapy.  19:1407-1414. 2008
2008 Therapeutic potential of mesenchymal stem cells producing interferon-α in a mouse melanoma lung metastasis modelSTEM CELLS.  26:2332-2338. 2008
2008 Silencing of transforming growth factor-β1 in situ by RNA interference for breast cancer: Implications for proliferation and migration in vitro and metastasis in vivoClinical Cancer Research.  14:4961. 2008
2008 Telomere maintenance in laser capture microdissection - Purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivoClinical Cancer Research.  14:4971. 2008
2008 Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis modelGene Therapy.  15:1446-1453. 2008
2008 Clinical significance of a novel single nucleotide polymorphism in the 5′ untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinomaFrontiers in Bioscience.  13:1050-1061. 2008
2008 Therapeutic potential of genetically modified mesenchymal stem cellsGene Therapy.  15:711-715. 2008
2008 Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasisMolecular Therapy.  16:871-878. 2008
2007 Bone homing of mesenchymal stem cells by ectopic α4 integrin expressionFederation proceedings.  21:3917-3927. 2007
2007 Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP ,modelCancer Research.  67:5789-5797. 2007
2007 Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirusGene Therapy.  14:627-637. 2007
2007 Notch1 augments intracellular trafficking of adeno-associated virus type 2Journal of Virology.  81:2069-2073. 2007
2007 Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathwayGene Therapy.  14:138-146. 2007
2006 Airway epithelium directed gene therapy for cystic fibrosisMedicinal Chemistry.  2:499-503. 2006
2006 Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's diseaseNeurobiology of Disease.  23:502-511. 2006
2006 Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screeningGene Therapy.  13:781-788. 2006
2006 Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligandsGene Therapy.  13:29-39. 2006
2005 Determination of osteoprogenitor-specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transductionBBA - Gene Structure and Expression.  1731:95-103. 2005
2005 Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myelomaCancer Research.  65:10041-10049. 2005
2005 Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivoHuman Gene Therapy.  16:1047-1057. 2005
2005 Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancerClinical Cancer Research.  11:1342-1347. 2005
2005 Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptorCancer Gene Therapy.  12:26-34. 2005
2004 Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvantHuman Gene Therapy.  15:856-864. 2004
2004 Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging.Journal of Clinical Oncology.  22:742. 2004
2004 Adeno-Associated Virus 2-Mediated Antiangiogenic Cancer Gene Therapy: Long-Term Efficacy of a Vector Encoding Angiostatin and Endostatin over Vectors Encoding a Single FactorCancer Research.  64:1781-1787. 2004
2004 Anti-angiogenic gene therapy for cancer (review).International Journal of Oncology.  25:335-343. 2004
2004 Delivery of DNA to tumor cells in vivo using adeno-associated virus.Methods in Molecular Biology.  246:237-243. 2004
2004 Gene therapy for osteoinductionCurrent Gene Therapy.  4:287-296. 2004
2004 Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapyHuman Gene Therapy.  15:1197-1206. 2004
2004 Parvovirus vectors for cancer gene therapyExpert Opinion on Biological Therapy.  4:53-64. 2004
2002 Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligandsJournal of Virology.  76:12900-12907. 2002
2002 Adenoassociated virus vectors for genetic immunizationImmunologic Research.  26:247-253. 2002
2001 Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: Implications for ex vivo immunotherapyJournal of Virology.  75:9493-9501. 2001
2001 Adeno-associated virus for cancer gene therapyCancer Research.  61:6313-6321. 2001
1999 Adeno-associated virus 2-mediated transduction and erythroid lineage- restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cellsJournal of Hematotherapy.  8:585-592. 1999
1998 Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expressionJournal of Virology.  72:9835-9843. 1998
1998 Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their eliminationJournal of Virology.  72:5472-5480. 1998
1998 Recombinant human parvovirus B19 vectors: Erythroid cell-specific delivery and expression of transduced genesJournal of Virology.  72:5224-5230. 1998
1998 Adeno-associated virus type 2-mediated gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein transgene expression in human cells in vitro and murine tissues in vivoJournal of Virology.  72:1593-1599. 1998
1997 Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+hematopoietic progenitor cells: Donor variation and correlation of transgene expression with cellular differentiationJournal of Virology.  71:8262-8267. 1997
1997 Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retinaCurrent Eye Research.  16:949-956. 1997
1997 Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expressionProceedings of the National Academy of Sciences.  94:10879-10884. 1997
1997 Encapsidation of adeno-associated virus type 2 rep proteins in wild- type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cellsJournal of Virology.  71:7361-7371. 1997
1997 Adeno-associated virus 2-mediated gene transfer in vivo: Organ-tropism and expression of transduced sequences in miceGene.  190:203-210. 1997
1997 Adeno-associated virus type 2 DNA replication in vivo: Mutation analyses of the D sequence in viral inverted terminal repeatsJournal of Virology.  71:3077-3082. 1997
1997 Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivoJournal of Virology.  71:3098-3104. 1997
1997 Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cellsHuman Gene Therapy.  8:275-284. 1997
1996 Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: Selective encapsidation of viral genomes in progeny virionsJournal of Virology.  70:1668-1677. 1996
1996 Adeno-associated virus 2-mediated transduction and erythroid lineage-specific expression in human hematopoietic progenitor cellsCurrent Topics in Microbiology and Immunology.  218:93-117. 1996
1996 Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: Human megakaryocytic leukaemia cells are non-permissive for AAV infectionJournal of General Virology.  77:1111-1122. 1996
1995 Rescue and replication signals of the adeno-associated virus 2 genomeJournal of Molecular Biology.  250:573-580. 1995
1995 Mouse silver. Mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17Nucleic Acids Research.  23:154-158. 1995
1995 Cord Blood Transplantation and the Potential for Gene Therapy: Gene Transduction Using a Recombinant Adeno‐Associated Viral VectorAnnals of the New York Academy of Sciences.  770:105-115. 1995
1995 Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2Journal of Virology.  69:8096-8101. 1995
1994 Suppression of human α-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectorsJournal of Experimental Medicine.  179:733-738. 1994
1994 Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter regionJournal of Investigative Dermatology.  102:744-748. 1994
1992 A cis‐Acting Element Involved in Mouse Tyrosinase Gene Expression and Partial Purification of its Binding ProteinPigment Cell Research.  5:155-161. 1992
1992 Amelioration of clinical severity through raised fetal hemoglobin in sickle cell anaemiaIndian Journal of Pediatrics.  59:85-90. 1992
1992 Enzymes of the Pentose Phosphate Pathway in Glutathione-Regulated Membrane Protection in β-ThalassaemiaClinical Chemistry and Laboratory Medicine.  30:481-484. 1992
1992 Enzymes of the pentose phosphate pathway in glutathione-regulated membrane protection in β-thalassaemiaEuropean journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.  30:481-484. 1992
1990 Elevated G gamma:A gamma globin chain ratio in homozygous beta thalassemia.Clinical Biochemistry.  23:529-531. 1990
1990 Elevated Gγ:Aγ globin chain ratio in homozygous beta thalassemiaClinical Biochemistry.  23:529-531. 1990
1989 Influence of gamma chains in in vitro globin synthesis in β° and β+ homozygous thalassaemiaMedical Science Research.  17:409-410. 1989

Education And Training

  • Doctor of Philosophy in Genetics, University of Madras 1989
  • Master's Level Degree in Genetics, University of Madras 1984
  • Full Name

  • Selvarangan Ponnazhagan